Showing 1 - 6 results of 6 for search 'Ulrika Wählby Hamrén', query time: 0.03s Refine Results
  1. 1
    Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials

    Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials by Vaishali S. Mankad, Amanda Leach, Yue Chang, Ulrika Wählby Hamrén, Alexandre Kiazand, Robert J. Kubiak, Therese Takas, Tonya Villafana, Manish Shroff

    Published 2024-06-01
    Get full text
    Article
  2. 2
    Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial

    Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controll... by Mary N. Brown, Rainard Fuhr, Jutta Beier, Hong-Lin Su, Yingxue Chen, Henrik Forsman, Ulrika Wählby Hamrén, Helen Jackson, Ajay Aggarwal

    Published 2019-02-01
    Get full text
    Article
  3. 3
    Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

    Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodil... by Victor Balaguer, Muna Albayaty, Eulalia Jimenez, Ulrika Wählby-Hamrén, Carol Astbury, Beatriz Seoane, Marie-Pierre Malice, Alejhandra Lei, Ajay Aggarwal, Ioannis Psallidas

    Published 2020-09-01
    Get full text
    Article
  4. 4
    A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

    A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults by Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin

    Published 2025-01-01
    Get full text
    Article
  5. 5
    Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

    Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials by Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana

    Published 2024-04-01
    Get full text
    Article
  6. 6
    Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

    Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials by Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana

    Published 2023-07-01
    Get full text
    Article

Search Tools: